Navigation Links
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
Date:5/26/2011

MOUNTAIN VIEW, Calif., May 26, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a debilitating neurological disorder. Common symptoms of migraine include recurrent headaches, nausea, phonophobia (sensitivity to sound) and photophobia (sensitivity to light).

"This NDA submission marks a major corporate milestone for MAP Pharmaceuticals and brings us one step closer to our goal of providing the underserved migraine patient population with a potential new treatment option," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Our comprehensive development program evaluated LEVADEX in approximately 1,000 patients for up to one year, treating nearly 10,000 migraines. If approved by the FDA, LEVADEX could potentially provide a new treatment option for migraine sufferers, including the millions of patients whose migraines are not well treated today."

The 505(b)(2) NDA submission is based on a comprehensive development program for LEVADEX, and includes efficacy and safety data from the Phase 3 FREEDOM-301 clinical trial that has been presented at scientific conferences and was recently published in Headache: The Journal of Head and Face Pain. In the FREEDOM-301 trial, patients self-administered LEVADEX at home using the Company's proprietary TEMPO® inhaler. LEVADEX contains a novel formulation of dihydroergotamine (DHE).  Patients taking LEVADEX in this pivotal trial had statistically significant improvement at two hours compared to patients on placebo for all four c
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Watson Acquires Specifar Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
3. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
4. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
5. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
6. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
7. Vanda Pharmaceuticals Reports First Quarter 2011 Results
8. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
9. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... WEST PALM BEACH, Fla. , May 21, ... Inc. (NYSE: FCN ), the global ... and enhance their enterprise value (the "Company"), announced ... sciences focused personnel that were formerly included within ... Forensic and Litigation Consulting segment to form a ...
(Date:5/21/2013)... 2013 Custom Learning Designs, Inc.(CLD) ... solution using Tin Can API combined with its ... is a leading developer of training content and ... worldwide. , Tin Can API is a ... and trainers more accurately measure the Return on ...
(Date:5/21/2013)... a new study led by George Washington University ... nucleation of ice in small droplets is strongly ... at the nanoscale. The formation of ice at ... question whose answer also has important implications for ... crystallization of ice from supercooled water is generally ...
(Date:5/21/2013)... 2013 The congress of the ... is the biggest congress in Europe ... participants are in Istanbul to ... New pioneering studies have been presented: / ... ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" By ...
Breaking Biology Technology:FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3
... (NYSE: AOB ), a leading manufacturer and distributor ... the Company will attend the Credit Suisse Asian Technology,Conference ... China as well as,the 3rd Semi-Annual Investor Tour of ... September 11, 2007 in Beijing, China. AOBO management ...
... OXFORD, N.C., Sept. 4 Catalyzing an entire,new ... of the newly,established Biofuels Center of North Carolina, ... of directors meeting. Funded with a $5 ... non-profit corporation will in coming years implement North,Carolina,s ...
... Pharmaceutical Manufacturing and Biotechnology Middle East (PABME) 27-29 ... ... The Middle East,market for pharmaceutical manufacturing and biotechnology, already valued,at over US$ ... -- Dubai is the commercial, scientific and financial center of the ...
Cached Biology Technology:American Oriental Bioengineering Announces Participation in September Investor Conferences 2N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation 2N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation 3
(Date:5/21/2013)... shape is an uphill battle? Try staying fit in ... withers muscle and bone. , That,s the challenge a ... a new three-year, $1.2 million grant from NASA. Their ... multiyear exploratory missions. , "You could give astronauts the ... get them to stick to it, it isn,t going ...
(Date:5/21/2013)... of insulin action in cells in precise detail like ... what goes wrong in diabetes. , The breakthrough ... from Sydney,s Garvan Institute of Medical Research, is now ... journal Cell Metabolism . , First discovered in ... in the body because it helps us lower blood ...
(Date:5/20/2013)... 20, 2013) University of Minnesota Medical School researchers ... partnership with the University,s Brain Tumor Program, have developed ... tumors (MPNST) that allow them to discover new genes ... The research was published this week in the journal ... transposon method, researchers in the lab of David Largaespada, ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2
... Harvard Medical School have found that a common cancer protein ... cells: It helps regulates memory formation and may be implicated ... that drives many types of solid tumors and blood cancers. ... the first revelation that cyclin E has a crucial role ...
... of the genes that support life in extreme environments, researchers ... has been awarded from the National Science Foundation, or NSF, ... heteroclitus , a species known to have evolved extremely high ... led by LSU Associate Professor of Biological Sciences Andrew Whitehead, ...
... the unsuspecting bug for a tasty snack, but in an ... larvae are able to lure their amphibious would-be predators and ... today in the online journal PLoS ONE , researchers ... off this feat. According to the researchers, larvae of ...
Cached Biology News:Cancer protein's surprising role as memory regulator 2Louisiana State University leads collaborative effort to identify genes supporting life in extreme conditions 2